ClinConnect ClinConnect Logo
Search / Trial NCT06624267

Test of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion

Launched by UNIVERSITY HOSPITAL BISPEBJERG AND FREDERIKSBERG · Sep 30, 2024

Trial Information

Current as of August 29, 2025

Not yet recruiting

Keywords

Microvascular Disease Microvascular Complications Of The Heart Microvascular Complications Of The Brain Microvascular Disease Patophysiology Diabetes Type 2 Dementia

ClinConnect Summary

This clinical trial is studying how well a special imaging test called [15O]H2O-PET can measure blood flow in the brain, particularly in older adults who may have small vessel disease (SVD) related to conditions like diabetes and dementia. Researchers want to understand how reduced blood flow in the brain and heart might affect thinking abilities and overall fitness in people with type 2 diabetes. The goal is to find better ways to diagnose and treat these issues, since many older adults experience problems with small blood vessels that aren’t addressed by current treatments.

To participate in the trial, individuals must be over 60 years old, not have been diagnosed with type 2 diabetes, and be able to speak and understand Danish for testing purposes. Participants will undergo imaging tests to assess their brain and heart health and may engage in physical activities to see if it helps improve their cognitive function. It’s important to note that those with certain medical conditions, like significant heart or brain issues, or who are already exercising intensely, won’t be eligible. This trial aims to shed light on the connections between heart health, brain function, and diabetes in older adults.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age \> 60 years
  • No diagnosis of T2D according to WHO\'s criteria.
  • Speaks and understands Danish (required for reliable cognitive testing)
  • Able to provide informed and written consent
  • Exclusion Criteria:
  • Moderate to high intensity training \>2 times/week.
  • Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \<45%), asthma.
  • Previous stroke or significant neurological disease including cognitive dysfunction.
  • Ongoing depression.
  • Hypothyroidism
  • Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.

About University Hospital Bispebjerg And Frederiksberg

University Hospital Bispebjerg and Frederiksberg is a leading academic medical institution in Denmark, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital integrates cutting-edge scientific inquiry with patient-centered care, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. The institution emphasizes a strong commitment to ethical standards and regulatory compliance, ensuring that all trials are designed to enhance medical knowledge and improve patient outcomes. With a focus on a wide range of therapeutic areas, University Hospital Bispebjerg and Frederiksberg strives to contribute significantly to the global medical community and the advancement of evidence-based practice.

Locations

Copenhagen, , Denmark

Patients applied

0 patients applied

Trial Officials

Thomas EHJ Primary Investigator, Medical Doctor

Principal Investigator

University Hospital Bispebjerg and Frederiksberg

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported